Marker Therapeutics Initiates First Off-the-Shelf T Cell Therapy Trial with Promising Early Safety Data
核心洞察
Marker Therapeutics successfully treated the first patient in its Phase 1 RAPID study with MT-401-OTS, an off-the-shelf multi-antigen recognizing T cell therapy targeting acute myeloid leukemia and myelodysplastic syndromes.
The initial patient received 100x10⁶ cells and showed no treatment-related adverse events after 28 days of monitoring, consistent with the favorable safety profile of MAR-T cell therapies.
The off-the-shelf approach aims to accelerate treatment delivery to as fast as 72 hours using commercially available donor material, potentially addressing manufacturing bottlenecks in personalized cell therapies.
Marker Therapeutics has achieved a significant milestone in cell therapy development by successfully treating the first patient with its off-the-shelf (OTS) multi-antigen recognizing T cell product, marking a potential breakthrough in addressing manufacturing delays that have limited broader access to personalized cancer immunotherapies.
The Houston-based clinical-stage immuno-oncology company announced that the initial patient in its Phase 1 RAPID study received MT-401-OTS at a dose of 100x10⁶ cells and was monitored for 28 days with encouraging preliminary safety results. The therapy was well tolerated with no treatment-related adverse events, consistent with the favorable safety profile previously reported for MAR-T cell therapies.
Addressing Manufacturing Bottlenecks in Cell Therapy
"One of the biggest limitations to cell therapy is the time-consuming manufacturing of individualized products," said Juan Vera, M.D., President and CEO of Marker Therapeutics. "With our OTS product, we are aiming to remove this bottleneck and provide a fast treatment option for patients with aggressive and rapidly progressing diseases."
The company's off-the-shelf approach utilizes commercially available leukapheresis material from healthy donors, which Marker believes can facilitate large-scale manufacturing and expedite treatment delivery to as fast as 72 hours while enabling broader scalability and accessibility at a lower per-dose cost.
Novel Multi-Antigen Platform Technology
MT-401-OTS represents a multi-antigen recognizing T cell product that targets four different tumor antigens upregulated in cancer cells: Survivin (搜索), PRAME (搜索), NY-ESO-1 (搜索), and WT-1. The MAR-T cell platform is a non-genetically modified cell therapy approach that selectively expands tumor-specific T cells capable of recognizing a broad range of tumor antigens.
Unlike other T cell therapies, MAR-T cells can recognize hundreds of different epitopes within up to six tumor-specific antigens, potentially reducing the possibility of tumor escape. Since MAR-T cells are not genetically engineered, Marker believes its product candidates will be easier and less expensive to manufacture with an improved safety profile compared to current engineered T cell approaches.
Clinical Trial Design and Patient Population
The Phase 1 multicenter, open-label RAPID trial (NCT06552416) is evaluating the safety and efficacy of escalating doses of MT-401-OTS in patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), with potential expansion to other indications.
To facilitate the OTS program, Marker has established a cellular inventory from commercially available leukapheresis material carefully selected to cover a large patient population with partially human leukocyte antigen (HLA) matched material. This approach has been validated and extensively tested in clinical settings at Baylor College of Medicine in the context of virus-specific T cells.
Promising Results in Lymphoma Program
While advancing the off-the-shelf program, Marker continues to focus on its lead asset MT-601 in the ongoing Phase 1 APOLLO study for lymphoma patients. The company recently reported promising clinical efficacy data showing an objective response rate of 66% with durable complete responses in patients with non-Hodgkin lymphoma. Marker believes this lymphoma program has the potential to qualify for expedited approval.
Non-Dilutive Funding Support
The OTS program is supported by non-dilutive funding from multiple federal agencies, including the National Cancer Institute of the National Institutes of Health (Award Number 1R44CA285177), the Food and Drug Administration Department of Health and Human Services (R01FD007272), and the Cancer Prevention and Research Institute of Texas (Award Number DP210042). This funding allows the company to proceed with the OTS program without affecting its financial runway or efforts to advance MT-601.
Clinical Experience and Future Development
Marker's approach builds on extensive clinical experience, with more than 200 patients enrolled across various hematological and solid tumor indications showing that the company's autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses.
"As we enroll additional patients in the Phase 1 RAPID study, we will continue to closely monitor the safety and long-term treatment effects of our OTS product," concluded Dr. Vera. "The collected data from this trial will serve as a foundation for refining and understanding the performance of MAR-T cells as an OTS product to potentially expand the OTS approach to other product candidates in our pipeline with the goal to accelerate time to treatment in other indications."